Consequently, the ESRP1-P-Luc2 reporter system proved to be a reliable tool for noninvasively monitoring the pharmacodynamic effects of 5-Aza-CdR treatment, specifically its activation of the ESRP1 promoter, in this subcutaneous RCC model. The gene discussed is ESRP1; the disease is renal cell carcinoma.